Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
89
Views
22
CrossRef citations to date
0
Altmetric
Original Research

Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women

Abdelhabib Semlali1 Genome Research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi ArabiaCorrespondence[email protected]
,
Maroua Jalouli2 Centre de recherche du CHU de Québec, L’Hôtel-Dieu de Québec, Department of Molecular Biology, Medical Biochemistry and Pathology, Université Laval, Quebec, QC, Canada
,
Narasimha Reddy Parine1 Genome Research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
,
Abdullah Al Amri1 Genome Research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
,
Maha Arafah3 College of Medicine, King Saud University
,
Abdulrahman Al Naeem4 Department of Women’s Imaging, King Fahad Medical City
,
Sanaa Abdullah Ajaj5 Department of Family Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
,
Mahmoud Rouabhia6 Groupe de Recherche en Écologie Buccale, Department of Stomatology, Faculty of Dentistry, Université Laval, Quebec, QC, Canada
&
Mohammad Saud Alanazi1 Genome Research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
 show all
Pages 1207-1216 | Published online: 24 Feb 2017

Figures & data

Table 1 Clinical characteristics of study subjects

Figure 1 Immunohistochemical determination of TLR-4 protein expression in normal and breast cancer tissues. (A) Representative sections (×200) of positive immunostaining of TLR-4 protein expression in normal breast tissues (a and b) and ER− breast cancer tissues (c and d). The staining of samples from ER− premenopausal patients is illustrated in (a and c) and from ER− postmenopausal patients in (b and d). Tissues were immunostained using specific TLR-4 antibodies. (B) TLR-4 positive staining was estimated as follows: 0 point, no positive staining; 1 point, <20% positive staining; 2 points, 21%–50% positive staining; 3 points, 51%–75% positive staining; and 4 points, >75% positive staining.

Abbreviations: TLR-4, Toll-like receptor 4; ER, estrogen receptor.
Figure 1 Immunohistochemical determination of TLR-4 protein expression in normal and breast cancer tissues. (A) Representative sections (×200) of positive immunostaining of TLR-4 protein expression in normal breast tissues (a and b) and ER− breast cancer tissues (c and d). The staining of samples from ER− premenopausal patients is illustrated in (a and c) and from ER− postmenopausal patients in (b and d). Tissues were immunostained using specific TLR-4 antibodies. (B) TLR-4 positive staining was estimated as follows: 0 point, no positive staining; 1 point, <20% positive staining; 2 points, 21%–50% positive staining; 3 points, 51%–75% positive staining; and 4 points, >75% positive staining.

Table 2 Frequencies of TLR-4 gene polymorphism in breast cancer

Table 3 Genotype frequencies of TLR-4 in breast cancer patients aged <48 years versus control

Table 4 Genotype frequencies of TLR-4 in breast cancer patients aged >48 years versus control

Table 5 Genotype frequencies of TLR-4 in ER− breast cancer patients versus control

Table 6 Genotype frequencies of TLR-4 in ER+ breast cancer patients versus control

Table S1 Characteristics of selected TLR-4 polymorphisms

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.